Johnson & Johnson posts steep Q3 profit drop, but sales climb
Johnson & Johnson reported a 96% drop in Q3 net profit to $210M, driven by talc litigation charges and acquisition costs, but sales rose 5.9% to $25.4B. Adjusted EPS fell 7.5% to $2.59. The company raised its 2026 earnings forecast to $11.05-$11.15 per share and sales to $101B-$101.4B.
How this was made
The 30-second read
Why it matters
The earnings miss highlights litigation risk and integration costs, while the guidance raise signals confidence in underlying business momentum.
Market read
The report provides fresh earnings data and guidance for a mega‑cap health‑care stock, creating immediate trading considerations.
What to watch
One‑off talc litigation charge and acquisition costs are non‑recurring; core sales growth remains solid.
Background
Johnson & Johnson is a diversified health‑care conglomerate with significant exposure to pharmaceuticals, medical devices, and consumer health products.
Ticker impact
Johnson & Johnson reported Q3 net profit down 96% to $210M but raised its 2026 full-year earnings forecast to $11.05‑$11.15 per share.
likely pressure as the market prices in the profit miss despite the higher guidance
The sharp earnings decline is material, yet the upward revision of full‑year earnings provides a mitigating catalyst.
Market effects
Healthcare sector may see modest pullback as a large‑cap pharma beats earnings expectations on guidance but misses profit.
U.S. market could see slight dip in pharma indices in after‑hours trading.
Limited; impact confined to U.S. equities and health‑care ETFs.
Counterpoint
The raised full‑year earnings forecast could attract long‑term buyers despite the quarterly loss.
Key entities
- companyFirefly Bio
Biotech acquired by Johnson & Johnson, contributing to acquisition costs.
- companySail Biomedicines
Partner in a strategic collaboration with Johnson & Johnson.
